25B-NBOMe

25B-NBOMe (NBOMe-2C-B, Cimbi-36, Nova, BOM 2-CB) is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent full agonist for the 5HT2A receptor. Anecdotal reports from users suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 250–500 µg, making it a similar potency to other phenethylamine derived hallucinogens such as Bromo-DragonFLY. Duration of effects lasts about 12–16 hours, although the parent compound is rapidly cleared from the blood when used in the radiolabeled form in tracer doses. The carbon-11 labeled version of this compound (Cimbi-36) was synthesized and validated as a radioactive tracer for positron emission tomography (PET) in Copenhagen. As a 5-HT2A receptor agonist PET radioligand, Cimbi-36 was hypothesized to provide a more functional marker of these receptors. Also, Cimbi-36 is investigated as a potential marker of serotonin release and thus could serve as an indicator of serotonin levels in vivo. Cimbi-36 is now undergoing clinical trials as a PET-ligand in humans. 25B-NBOMe has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram. Such a dose is only 1/300th the dose expected to be hallucinogenic to humans and it is expected that recreational use would greatly exceed doses determined to be safe to humans. One case has been reported on where 25B-NBOMe was identified as the cause of death for a 17-year-old boy. The drug was also implicated in the death of an 18-year old male, however it was not reported whether the presence of the drug was confirmed postmortem. Several deaths have been attributed to its close analogue 25I-NBOMe. As of October 31, 2016; 25B-NBOMe is a controlled substance (Schedule III) in Canada. Banned as a narcotic drug since May 5, 2015. In Sweden, the Riksdag added 25B-NBOMe to schedule I ('substances, plant materials and fungi which normally do not have medical use') as narcotics in Sweden as of August 1, 2013, published by Medical Products Agency in their regulation LVFS 2013:15 listed as 25B-NBOMe 2-(4-bromo-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin. This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.